Examining the neuropeptide linked to sleep regulation, stress modulation, and neuroendocrine function in preclinical research.
Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring neuropeptide composed of nine amino acids with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. First isolated in 1977 by Swiss researchers from the cerebral venous blood of rabbits during electrically induced sleep, DSIP has since become a subject of considerable interest in neuroscience and endocrinology research. The peptide is found in both free and bound forms in the hypothalamus, limbic system, and various peripheral organs, suggesting a broad physiological role beyond its original association with sleep.
Despite its name, DSIP's biological significance extends well beyond the induction of delta-wave sleep. Decades of preclinical investigation have revealed potential involvement in stress response regulation, circadian rhythm modulation, and neuroendocrine signaling. It is available to researchers as a 15mg lyophilized powder at $45 per vial, providing a stable and convenient format for laboratory studies.
The discovery of DSIP arose from pioneering work by Monnier and Schoenenberger at the University of Basel. Their experiments involved stimulating the thalamus of donor rabbits to induce slow-wave sleep, then collecting dialysates of cerebral venous blood and infusing them into recipient rabbits. The recipients exhibited increased delta-wave electroencephalographic activity, and subsequent purification efforts identified the responsible nonapeptide. This landmark finding opened an entirely new avenue of neuropeptide research.
Throughout the 1980s and 1990s, numerous research groups investigated DSIP across a range of preclinical models. Studies in rodents demonstrated that administration of DSIP could alter sleep architecture, particularly enhancing slow-wave sleep episodes without significantly suppressing rapid eye movement (REM) sleep. Other lines of investigation explored its effects on corticotropin and cortisol levels, revealing a possible role in modulating the hypothalamic-pituitary-adrenal (HPA) axis. Research also examined DSIP in the context of opioid withdrawal models, where it appeared to attenuate certain stress-related physiological markers. While these findings remain at the preclinical stage, they have sustained scientific interest in the peptide for nearly five decades.
DSIP is a nonapeptide with the primary structure Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, corresponding to a molecular weight of approximately 849 Da. Its relatively small size and lack of disulfide bonds give it a flexible, largely unstructured conformation in aqueous solution. The N-terminal tryptophan residue and C-terminal glutamic acid residue contribute to the peptide's amphiphilic character, which may influence its interactions with cell membranes and receptor binding sites.
One notable characteristic of DSIP is its ability to cross the blood-brain barrier, a property that has been demonstrated in radiolabeled tracer studies using animal models. This capacity is somewhat unusual for peptides and is believed to be facilitated by a saturable transport mechanism rather than simple passive diffusion. The peptide is supplied as a white to off-white lyophilized powder with high purity, suitable for reconstitution with bacteriostatic water or sterile saline prior to use in research protocols.
DSIP is studied across several interconnected research domains. In sleep research, investigators use the peptide to examine its effects on sleep onset latency, sleep stage distribution, and circadian rhythm entrainment in animal models. These studies aim to clarify the neurochemical pathways through which DSIP may promote slow-wave sleep and whether its effects are mediated by direct receptor binding or through downstream modulation of other neurotransmitter systems such as serotonin and GABA.
Stress response research represents another major application. Preclinical studies have explored whether DSIP can influence the release of adrenocorticotropic hormone (ACTH) and cortisol under stress conditions, providing insights into its potential role as a neuroendocrine modulator. Additionally, researchers have investigated DSIP in oxidative stress models, where some evidence suggests the peptide may support antioxidant enzyme activity.
Neuroendocrine studies have examined DSIP's interactions with growth hormone secretion, luteinizing hormone release, and thermoregulatory processes. Its wide distribution across both central and peripheral tissues makes it a versatile tool for investigating peptide-mediated signaling in complex physiological systems.
Lyophilized DSIP should be stored at -20°C for long-term preservation, where it remains stable for up to 24 months when kept in its original sealed vial. Once reconstituted with bacteriostatic water or sterile saline, the solution should be refrigerated at 2-8°C and used within 30 days to ensure peptide integrity. Repeated freeze-thaw cycles should be avoided, as they can cause aggregation and degradation of the peptide. Researchers should use sterile technique and appropriate laboratory gloves during reconstitution and aliquoting to prevent contamination.
This product is sold exclusively for laboratory and scientific research purposes. It is not intended for human or veterinary use, diagnostic purposes, or therapeutic applications. All research must comply with applicable laws and institutional guidelines. By purchasing, you confirm you are a qualified researcher. Please review our full legal disclaimer.